SCHEMBL1470207

SCHEMBL1470207

CC(C)=CCC/C(C)=C/CC/C(C)=C/C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.92
ATM Q13315 1/20 0.92
KMT2A Q03164 3/20 0.64
KDM1A O60341 1/20 0.64
POLB P06746 1/20 0.62
FNTA P49354 10/20 0.61
FNTB P49356 10/20 0.61
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
ALDH1A1 P00352 1/20 0.57
CYP3A4 P08684 1/20 0.57
ALOX15 P16050 1/20 0.57
UGT1A1 P22309 1/20 0.57
TRPA1 O75762 1/20 0.56
SQLE Q14534 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9475040 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL7943006 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL3088919 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL10748886 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL10566443 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
Geranylgeranoic Acid SCHEMBL10781543 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
Geranylgeranoic Acid SCHEMBL10405196 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL9366045 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL7943004 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB
SCHEMBL3088917 1.00 KDM4E (0.92) KDM4EATMKMT2AKDM1APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7038067-B2 Process for synthesizing d-tocotrienols from 2-vinylchromane compound YASOO HEALTH, INC. (US) 2006-05-02 US claimed
US-20050124688-A1 Process for synthesizing d-tocotrienols from 2-vinylchromane compound YASOO HEALTH, INC. 2005-06-09 US claimed
WO-2005035491-A2 PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND YASOO HEALTH, INC. (US) 2005-04-21 WO claimed
EP-0332143-B1 11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] KURARAY CO (JP) 1994-03-16 EP claimed
US-5015746-A Esterification of prednisolone with 3,7,11-trimethyl-2,6,10-dodecatrienoic acid in the presence of disubstituted aminopyridines and a condensing agents KURARAY CO., LTD. (JP) 1991-05-14 US claimed
EP-0332143-A1 11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] KURARAY CO., LTD. (JP) 1989-09-13 EP claimed
US-4115417-A ENANTIOSELECTIVITY HOFFMANN-LA ROCHE INC. (US) 1978-09-19 US claimed
JP-62142137-A None JP disclosed
JP-1265085-A None JP disclosed
JP-1316397-A None JP disclosed
JP-1316396-A None JP disclosed
WO-2023072285-A1 ENOATE COMPOUND CONTAINING AROMATIC RING, AND PREPARATION THEREFOR AND USE THEREOF 中国农业大学 2023-05-04 WO disclosed
EP-3762476-A1 LUBRICANT AND REFRIGERANT COMPOSITIONS COMPRISING POLYALKYLENE GLYCOLS AND USES THEREOF Shrieve Chemical Products, Inc. (US) 2021-01-13 EP disclosed
EP-0332143-A1 11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] KURARAY CO., LTD. (JP) 1989-09-13 EP disclosed
US-4762829-A ANTICOAGULANTS EISAI CO., LTD. (JP) 1988-08-09 US disclosed
US-4742058-A AMIDES, ANTICOAGULANTS EISAI CO., LTD. (JP) 1988-05-03 US disclosed
JP-S62142137-A PRODUCTION OF E,E 3,7,11-TRIMETHYL-2,6,10-DODECATRIENOIC ACID KURARAY CO LTD 1987-06-25 JP disclosed
EP-0110397-A2 Polyprenyl compound and drug containing the same Eisai Co., Ltd. (JP) 1984-06-13 EP disclosed
US-4123465-A SELECTIVE HYDROGENATION CATALYSTS HOFFMANN-LA ROCHE INC. (US) 1978-10-31 US disclosed
US-4115417-A ENANTIOSELECTIVITY HOFFMANN-LA ROCHE INC. (US) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124688-A1 Process for synthesizing d-tocotrienols from 2-vinylchromane compound FDFT1, DHCR7, DDT KDM4E 3488/4885ATM 3372/4885KMT2A 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.